Lobbying registration dated 2026-03-30
Registrant: Gaby Bourbara
Client: AstraZeneca Canada Inc.
Targeted institutions:
Privy Council Office (PCO)
Health Canada (HC)
Indigenous Services Canada (ISC)
Innovation, Science and Economic Development Canada (ISED)
National Research Council (NRC)
Canadian Institutes of Health Research (CIHR)
National Defence (DND)
Natural Sciences and Engineering Research Council (NSERC)
Global Affairs Canada (GAC)
House of Commons
Prime Minister's Office (PMO)
Public Services and Procurement Canada (PSPC)
Atlantic Canada Opportunities Agency (ACOA)
Canadian International Trade Tribunal (CITT)
Treasury Board Of Canada Secretariat (TBS)
Senate of Canada
Canada Foundation for Innovation
Canadian Northern Economic Development Agency (CanNor)
Agriculture and Agri-Food Canada (AAFC)
Royal Canadian Mounted Police (RCMP)
International Development Research Centre (IDRC)
Canada Economic Development for Quebec Regions
Federal Economic Development Agency for Southern Ontario (FedDev)
Veterans Affairs Canada (VAC)
Public Health Agency of Canada (PHAC)
Patented Medicine Prices Review Board (PMPRB)
Finance Canada (FIN)
Canada Revenue Agency (CRA)
Competition Bureau Canada (COBU)
Acts: Patent Act
Government funding received:
Lobbying activity details:
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
Federally-funded Public Drug Plans, including the Non Insured Health Benefits program, with respect to reimbursement for drug products for beneficiaries.
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures.  Discussions on policies such as "patent box" and Investment Tax Credits.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as COVID-19 and RSV.
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada